"KCAS’ investment in talent and technology are positioning our organization as an outsourcing provider with the capabilities to stand out in the CRO industry.”
Kansas City, KS (PRWEB) November 16, 2016
KCAS Bioanalytical and Biomarker Services, a leading functional service contract research organization (CRO) has recently qualified five Flow Cytometry Immune Monitoring Panels for use in clinical trials.
“KCAS is committed to supporting the needs of the growing biopharmaceutical industry and is bringing multiple new technologies on line. Earlier this year we announced our expansion into Flow Cytometry. These newly-qualified off-the-shelf panels show that KCAS has the capabilities, expertise and experience to support our client’s development programs. KCAS’ investment in talent and technology are positioning our organization as an outsourcing provider with the capabilities to stand out in the CRO industry,” stated John Bucksath, CEO.
KCAS’ qualified Flow Cytometry panels include a TBNK Basic panel, T Cell Subset Panel, T Cell Receptor Panel, B Cell Panel and Dendritic Cell Panel. All five panels have been qualified in four plasma tube types: K2 EDTA, sodium heparin, acid citrate dextrose (ACD) and Cyto-Chex BCT. The Cyto-Chex BCT stabilizes all five panels for ten days. The other three plasma tube types are stable for 48-72 hours. KCAS offers these panels with two open channels to allow clients to custom design the panel with two CD markers of their choice.
“We choose these five panels to offer our clients a full spectrum of population analysis options, utilizing established phenotypic markers. Our clients benefit from the reliability of a pre-cocktailed panel and the flexibility to insert additional markers as needed. This decreases the cost of the study by reducing material costs and time invested in qualification steps of a 10 biomarker panel.” said Joyce Slusser, Senior Scientist. Currently, KCAS’ powerful analytical tests are utilized to measure TBNK in clinical trials.
KCAS Bioanalytical & Biomarker Services is a contract laboratory with 37+ years of bioanalytical expertise. Centrally located in Kansas City, KCAS provides small- and large-molecule PK, immunogenicity, and biomarker analysis operating a variety of equipment platforms to service a wide range of therapeutic areas. KCAS’ team leverages a highly scientific staff with an average tenure of 14 years at the company to provide clients of all sizes with expertise in robust assay development, validation, and sample analysis under non-GLP, GLP, and GCP conditions for discovery, preclinical and clinical studies. Our teams have developed and validated more than 5,500 bioanalytical assays and have undergone 16 FDA inspections. Learn more at: http://www.kcasbio.com